23andMe Holding Co.
MEUSW
NASDAQ Global Select1.38
USD
-0.13
- -
CIK
0001804591
ISIN
US90138Q3065
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
-57.54
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Anne Wojcicki
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 223 N. Mathilda Ave. Sunnyvale CA United States of America 94086
- IPO Date
- Jun 17, 2021
- CIK
- 0001804591
- Website
- 23andme.com
- Similar Companies
- Business
- 23andMe Holding Co., now operating as Chrome Holding Co. following its Chapter 11 reorganization, provides direct-to-consumer genetic testing services, including ancestry composition reports, family matching tools, trait insights, health predisposition reports, carrier status screenings, pharmacogenetics analysis, and subscription-based offerings such as 23andMe+ Premium with exome sequencing, biannual blood biomarker testing, telehealth services via the former Lemonaid Health platform including GLP-1 weight loss prescriptions, AI-powered insights through DaNA chatbot, and Total Health longevity service combining genetics with clinical preventive care; the company also monetizes its vast genetic database via research partnerships for drug discovery in areas like Parkinson's disease, inflammatory bowel disease, sickle cell trait, and lung cancer studies, as well as aggregated anonymized data sales to pharmaceutical firms and academic institutions. Founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza, 23andMe Holding Co. is headquartered in Sunnyvale, California, with prior operations centered in South San Francisco, and serves customers primarily in the United States, United Kingdom, Canada, and select international markets through its Personal Genome Service (PGS) kits requiring saliva samples processed via single nucleotide polymorphism genotyping. In recent major developments, the company filed for voluntary Chapter 11 bankruptcy protection in March 2025 in the U.S. Bankruptcy Court for the Eastern District of Missouri to facilitate an asset sale and resolve liabilities from a 2023 cyber incident, culminating in court approval of its Modified Fifth Amended Joint Plan on December 1, 2025, which cancels all outstanding shares including MEUSW warrants, establishes data breach settlement funds totaling up to $62 million for U.S. and Canadian claimants, approves a $305 million asset acquisition by TTAM Research Institute—a nonprofit led by co-founder Anne Wojcicki—over a competing $256 million bid from Regeneron Pharmaceuticals, winds down the Lemonaid Health subsidiary, implements a 1-for-20 reverse stock split in October 2024 to regain Nasdaq compliance before voluntary delisting, reconstitutes its board with new directors, and launches new genetic reports on emotional eating and homocysteine alongside operational restructuring to cut costs and extend cash runway.